Barclays Maintains Overweight on Repligen, Raises Price Target to $225

Barclays analyst Luke Sergott has maintained an Overweight rating on Repligen (NASDAQ:RGEN) and increased the price target from $175 to $225. This adjustment reflects a positive outlook for the company's performance.